cfDNA in pancreatic neuroendocrine carcinoma management with Cushing’s syndrome

oleh: Laura Gerard, David Barthelemy, Arnaud Gauthier, Valerie Hervieu, Jonathan Lopez, Benjamin Gibert, Helene Lasolle, Laurence Chardon, Jessica Garcia, Gérald Raverot, Léa Payen, Thomas Walter

Format: Article
Diterbitkan: Bioscientifica 2023-01-01

Deskripsi

We report a case of metastatic pancreatic neuroendocrine carcinoma associated with paraneoplastic Cushing’s syndrome, successively treated with five lines of treatment (platin-etoposide, LV5FU2-dacarbazine, FOLFIRINOX, pembrolizumab, and paclitaxel) and anti-secretory treatment. Circulating-free DNA (cfDNA) was analysed at each morphological evaluation starting from the second-line treatment. cfDNA changes were well correlated with the disease course, and cfDNA may be used as a predictive marker and/or as an early marker of response. In addition, the absolute count of atypical cells was elevated upon disease progression.